The story of Sildenafil offers a complicated case study for investors eyeing drug companies. While early sales were remarkable, current patent lapse and the emergence of cheaper versions have significantly impacted https://kalengxj422611.sharebyblog.com/40910601/the-blue-pill-and-big-pharma-a-dangerous-stake